Company news

Celularity Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

November 9, 2022

Celularity Promotes Two Executives in Executive Leadership Team

October 5, 2022

Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer

October 2, 2022

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

September 26, 2022

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

September 25, 2022

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

September 14, 2022

Celularity Announces Participation in Upcoming Investor Conferences

September 5, 2022

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

August 8, 2022

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

July 26, 2022

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

June 2, 2022

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 17, 2022

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 15, 2022

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 30, 2022

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

February 14, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

January 17, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

December 26, 2021

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

November 28, 2021

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

November 11, 2021

Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

September 19, 2021

Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President

September 14, 2021

Celularity Reports Second Quarter 2021 Financial Results

August 15, 2021

← Newer news releases

Decks

The 5 newest of 14 decks. Every deck is listed under its year.